Vol. 2025 No. 4 (2025)
Articles

Impact of NAC on inflammation and nutrition in hemodialysis

PDF
  • Oliver Evans
Oliver Evans
University of Toronto Faculty of Medicine,1 King's College Circle, Medical Sciences Building, Toronto, ON, M5S 1A8, Canada

Published 18-09-2025

Keywords

  • Hemodialysis,
  • N-Acetylcysteine,
  • Inflammatory Markers,
  • Nutrition

Copyright (c) 2025 Cambridge Science Advance

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

[1]
O. Evans, “Impact of NAC on inflammation and nutrition in hemodialysis”, Camb. Sci. Adv., vol. 2025, no. 4, pp. 1–6, Sep. 2025, doi: 10.62852/csa/2025/172.

Abstract

 Objective: To assess whether N-Acetylcysteine (NAC)treatment can improve inflammatory markers and nutritional status in patients undergoing Maintenance Hemodialysis (MHD). Methods: A total of 71 patients who had been on hemodialysis for more than 6 months were selected and randomly divided into an NAC treatment group (NAC 600 mg, twice daily,41 cases) and a control group (no medication,30 cases). Routine clinical data were collected, and a 3-month observation period was initiated. Inflammatory markers, including high-sensitivity C-reactive protein (h s-CRP), interleukin-6(IL-6), interleukin-10(IL-10), tumor necrosis factor (TNF), and homocysteine levels, were measured before and after treatment. Nutritional indicators, such as hemoglobin, serum albumin, and prealbumin levels, were also assessed before and after treatment. Results: After 3 months of NAC treatment in hemodialysis patients, h s-CRP and IL-6 levels significantly decreased compared to pre-treatment levels(both P<0.01).Homocysteine levels also significantly decreased(P<0.05).Hemoglobin, serum albumin, and prealbumin levels significantly increased(P<0.05 and P<0.01,respectively).The reduction in h s-CRP levels in female MHD patients was significantly greater than that in male patients(P<0.01).Conclusion: NAC treatment can reduce inflammatory marker levels and improve nutritional status in hemodialysis patients, thereby benefiting these patients from anti-inflammatory therapy.

PDF

References

  1. Block G, Port F K. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney dis- ease[J]. Semin Dial,2003,16(2):140-147.
  2. Himmelfarb J, Stenvinkel P, Ikizler T A, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia[J]. Kidney Int, 2002, 62(5): 1524-1538.
  3. Vaziri ND, Ni Z, Oveisi F, et al. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency [J]. Hypertension, 2002,39(1):135- 141.
  4. Hasdan G, Benchetrit S, Rashid G, et al. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide[J]. Kidney Int,2002,61(2): 586-590.
  5. Rauchova H, Pechanova O, Kunes J, et al. Chronic N-acetylcysteine administration prevents development of hypertension in N(omega)-nitro-L-arginine methyl ester-treated rats: the role of reactive oxygen species[J]. Hypertens Res, 2005, 28(5): 475-482.
  6. Tepel M, Van Der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial[J]. Circulation, 2003, 107(7): 992-995.
  7. Thaha M, Widodo, Pranawa W, et al. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients[J]. Clin Nephrol,2008,69(1):24-32.
  8. Friedman A N, Bostom A G, Laliberty P, et al. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study[J]. Am J Kidney Dis,2003,41(2):442-446.
  9. Scholze A, Rinder C, Beige J, et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure[J]. Circulation, 2004, 109(3): 369- 374.
  10. Nascimento M M, Suliman M E, Silva M, et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo -controlled study[J]. Perit Dial Int, 2010, 30(3):336-342.
  11. Yudkin J S, Kumari M, Humphries S E, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link[J]. Atherosclerosis, 2000,148(2):209- 214.
  12. Pigott R, Dillon LP, Hemingway I H, et al. Soluble forms of Eselectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells[J]. Biochem Biophys Res Commun, 1992,187(2): 584-589.
  13. Elhage R, Clamens S, Besnard S, et al. Involvement of interleukin-6 in atherosclerosis but not in the pevention of fatty streak formation by 17 beta-estradiol in apolipoprotein E-deficient mice[J]. Atherosclerosis, 2001,156(2): 315-320.
  14. Pachaly MA, de Nascimento M M, Suliman ME, et al. Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients[J]. Blood Purif, 2008,26(2):204-210.
  15. Dodd S, Dean O, Copolov D L, et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility[J]. Expert Opin Biol Ther,2008,8(12):1955-1962.
  16. Araki S, Dobashi K, Kubo K, et al. N-acetylcysteine inhibits induction of nitric oxide synthase in 3T3-L1adipo- cytes[J]. JU oeh,2007,29(4):417-429.
  17. Genest J.C-reactive protein: risk factor, biomarker and/or therapeutic target? [J]. Can J Cardiol,2010,26(Suppl A): 41-44.
  18. Yang Xiaoxia, Yang Yan Tao, Ma Li, et al. Correlation of BNP, CRP, TNF-α, IL-6 with the Diagnosis and Cardiac Function Classification of Chronic Congestive Heart Failure [J]. Journal of Lanzhou University: Medical Edition, 2012, 38(2): 40-42.
  19. Ridker P M. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence [J]. Circulation, 1998,97(17):1671-1674.
  20. Ducloux D, Klein A, Kazory A, et al. Impact of malnutrition-inflammation on the association between homocysteine and mortality[J]. Kidney Int,2006,69(2):331-335.
  21. Lakoski S G, Cushman M, Criqui M, et al. Gender and C-reactive protein: data from the multiethnic study of atherosclerosis (MESA)cohort[J]. Am Heart J,2006, 152(3):593-598.
  22. Ford E S, Giles W H, Mokdad A H, et al. Distribution and correlates of C-reactive protein concentrations among adult US women[J]. Clin Chem,2004,50(3):574-581.
  23. Norouzi V, Seifi M, Fallah S, et al. Effect of oral contraceptive therapy on homocysteine and C-reactive protein levels in women: an observational study[J]. Anadolu Kardiyol Derg, 2011, 11(8): 698-702.
  24. Caglar K, Hakim R M, Ikizler T A. Approaches to the reversal of malnutrition, inflammation, and atherosclerosis in end-stage renal disease[J]. Nutr Rev,2002,60(11): 378-387.
  25. Bergström J, Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view[J]. Am J Kidney Dis,1998,32(5):834-841.